<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Zydus Lifesciences Limited — News on 6ix</title>
<link>https://6ix.com/company/zydus-lifesciences-limited</link>
<description>Latest news and press releases for Zydus Lifesciences Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Sat, 25 Apr 2026 16:49:43 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/zydus-lifesciences-limited" rel="self" type="application/rss+xml" />
<item>
<title>Press Release Apr 25 2026</title>
<link>https://6ix.com/company/zydus-lifesciences-limited/news/press-release-apr-25-2026-6</link>
<guid isPermaLink="true">https://6ix.com/company/zydus-lifesciences-limited/news/press-release-apr-25-2026-6</guid>
<pubDate>Sat, 25 Apr 2026 16:49:43 GMT</pubDate>
<description>Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 25, 2026, titled "Zydus receives approval from DCGI to initiate Phase III trials of Zintrodiazine, a novel anti-malarial candidate".</description>
</item>
<item>
<title>Press Release Apr 16 2026</title>
<link>https://6ix.com/company/zydus-lifesciences-limited/news/press-release-apr-16-2026-21</link>
<guid isPermaLink="true">https://6ix.com/company/zydus-lifesciences-limited/news/press-release-apr-16-2026-21</guid>
<pubDate>Thu, 16 Apr 2026 16:47:54 GMT</pubDate>
<description>Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 16, 2026, titled "Zydus receives EIR for oncology injectable manufacturing facility in SEZ1, Ahmedabad".</description>
</item>
<item>
<title>Press Release Apr 08 2026</title>
<link>https://6ix.com/company/zydus-lifesciences-limited/news/press-release-apr-08-2026-8</link>
<guid isPermaLink="true">https://6ix.com/company/zydus-lifesciences-limited/news/press-release-apr-08-2026-8</guid>
<pubDate>Wed, 08 Apr 2026 13:44:53 GMT</pubDate>
<description>Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 08, 2026, titled "Zydus receives final approval from USFDA for Dapagliflozin Tablets, 5 mg and 10 mg".</description>
</item>
<item>
<title>Press Release Mar 21 2026</title>
<link>https://6ix.com/company/zydus-lifesciences-limited/news/press-release-mar-21-2026-3</link>
<guid isPermaLink="true">https://6ix.com/company/zydus-lifesciences-limited/news/press-release-mar-21-2026-3</guid>
<pubDate>Sat, 21 Mar 2026 12:16:11 GMT</pubDate>
<description>Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 21, 2026, titled "Zydus launches Semaglutide Injection in an innovative, reusable multi-dose pen device in India".</description>
</item>
<item>
<title>AeroDel signs exclusive licensing arrangement with Zydus for launching Aerolife Mini™, India's First Foldable, 'Always Attached' pMDI Enhancer</title>
<link>https://6ix.com/company/zydus-lifesciences-limited/news/aerodel-signs-exclusive-licensing-arrangement-with-zydus-for-launching-aerolife-minitm-indias-first-foldable-always-attached-pmdi-enhancer</link>
<guid isPermaLink="true">https://6ix.com/company/zydus-lifesciences-limited/news/aerodel-signs-exclusive-licensing-arrangement-with-zydus-for-launching-aerolife-minitm-indias-first-foldable-always-attached-pmdi-enhancer</guid>
<pubDate>Fri, 20 Mar 2026 04:30:00 GMT</pubDate>
<description>AeroDel Technology Innovations Pvt. Ltd., a Mumbai-based respiratory medical device company, announces an exclusive licensing arrangement with Zydus Lifesciences Limited for the commercial pan-India launch of its A202 device in March 2026. Developed and manufactured by AeroDel, A202 is being made available to patients as Aerolife Mini™.</description>
</item>
<item>
<title>Press Release Mar 19 2026</title>
<link>https://6ix.com/company/zydus-lifesciences-limited/news/press-release-mar-19-2026-2</link>
<guid isPermaLink="true">https://6ix.com/company/zydus-lifesciences-limited/news/press-release-mar-19-2026-2</guid>
<pubDate>Thu, 19 Mar 2026 13:27:50 GMT</pubDate>
<description>Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 19, 2026, titled "Zydus launches Aerolife Mini , to simplify inhaler use for asthma and COPD patients".</description>
</item>
<item>
<title>Press Release Mar 18 2026</title>
<link>https://6ix.com/company/zydus-lifesciences-limited/news/press-release-mar-18-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/zydus-lifesciences-limited/news/press-release-mar-18-2026-1</guid>
<pubDate>Wed, 18 Mar 2026 19:08:56 GMT</pubDate>
<description>Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 18, 2026, titled "Zydus and Torrent Pharma sign licensing agreement to co-market innovative Semaglutide Injection in India".</description>
</item>
<item>
<title>Press Release Mar 17 2026</title>
<link>https://6ix.com/company/zydus-lifesciences-limited/news/press-release-mar-17-2026-2</link>
<guid isPermaLink="true">https://6ix.com/company/zydus-lifesciences-limited/news/press-release-mar-17-2026-2</guid>
<pubDate>Tue, 17 Mar 2026 16:00:11 GMT</pubDate>
<description>Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 17, 2026, titled "Zydus and Lupin sign licensing agreement for co-marketing innovative Semaglutide Injection in India".</description>
</item>
<item>
<title>Press Release Mar 16 2026</title>
<link>https://6ix.com/company/zydus-lifesciences-limited/news/press-release-mar-16-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/zydus-lifesciences-limited/news/press-release-mar-16-2026-1</guid>
<pubDate>Tue, 17 Mar 2026 00:15:08 GMT</pubDate>
<description>Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 16, 2026, titled "Sentynl Therapeutics Enters into Agreement with PRG S&T to License Molecule for Hutchinson-Gilford Progeria Syndrome".</description>
</item>
<item>
<title>Press Release Mar 14 2026</title>
<link>https://6ix.com/company/zydus-lifesciences-limited/news/press-release-mar-14-2026-2</link>
<guid isPermaLink="true">https://6ix.com/company/zydus-lifesciences-limited/news/press-release-mar-14-2026-2</guid>
<pubDate>Sat, 14 Mar 2026 17:39:53 GMT</pubDate>
<description>Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 14, 2026, titled "Zydus new drug discovery, Desidustat licensed to China Medical System Holdings receives approval from NMPA of China".</description>
</item>
<item>
<title>Press Release Mar 13 2026</title>
<link>https://6ix.com/company/zydus-lifesciences-limited/news/press-release-mar-13-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/zydus-lifesciences-limited/news/press-release-mar-13-2026-1</guid>
<pubDate>Fri, 13 Mar 2026 14:02:47 GMT</pubDate>
<description>Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 13, 2026, titled "Zydus receives final approval from USFDA for Cevimeline Hydrochloride Capsules 30mg".</description>
</item>
<item>
<title>Press Release Mar 12 2026</title>
<link>https://6ix.com/company/zydus-lifesciences-limited/news/press-release-mar-12-2026-4</link>
<guid isPermaLink="true">https://6ix.com/company/zydus-lifesciences-limited/news/press-release-mar-12-2026-4</guid>
<pubDate>Thu, 12 Mar 2026 18:21:02 GMT</pubDate>
<description>Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 12, 2026, titled "Zydus expands companion diagnostics portfolio with the launch of AI-powered Continuous Glucose Monitor DiasensTM and GlucoLiveTM".</description>
</item>
<item>
<title>Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs</title>
<link>https://6ix.com/company/zydus-lifesciences-limited/news/agenus-triggers-first-dollar20m-contingent-payment-under-zydus-life-sciences-collaboration-to-support-botbal-manufacturing-needs-3</link>
<guid isPermaLink="true">https://6ix.com/company/zydus-lifesciences-limited/news/agenus-triggers-first-dollar20m-contingent-payment-under-zydus-life-sciences-collaboration-to-support-botbal-manufacturing-needs-3</guid>
<pubDate>Tue, 10 Mar 2026 11:30:00 GMT</pubDate>
<description>LEXINGTON, Mass., March 10, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has triggered the first $20 million contingent payment under its previously disclosed strategic collaboration with Zydus Lifesciences Ltd.</description>
</item>
<item>
<title>Press Release Feb 28 2026</title>
<link>https://6ix.com/company/zydus-lifesciences-limited/news/press-release-feb-28-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/zydus-lifesciences-limited/news/press-release-feb-28-2026-1</guid>
<pubDate>Sat, 28 Feb 2026 16:13:51 GMT</pubDate>
<description>Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 28, 2026, titled "Zydus receives final approvals from USFDA for Ivermectin Tablets USP, 3 mg and Dapsone Tablets USP, 25 mg and 100 mg".</description>
</item>
<item>
<title>Press Release Feb 27 2026</title>
<link>https://6ix.com/company/zydus-lifesciences-limited/news/press-release-feb-27-2026-2</link>
<guid isPermaLink="true">https://6ix.com/company/zydus-lifesciences-limited/news/press-release-feb-27-2026-2</guid>
<pubDate>Fri, 27 Feb 2026 19:50:56 GMT</pubDate>
<description>Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 27, 2026, titled "Zydus Lifesciences announces successful clinical development of Pembrolizumab biosimilar FYB206, marking a milestone toward USFDA filing".</description>
</item>
<item>
<title>Press Release Feb 25 2026</title>
<link>https://6ix.com/company/zydus-lifesciences-limited/news/press-release-feb-25-2026-2</link>
<guid isPermaLink="true">https://6ix.com/company/zydus-lifesciences-limited/news/press-release-feb-25-2026-2</guid>
<pubDate>Wed, 25 Feb 2026 23:48:44 GMT</pubDate>
<description>Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 25, 2026, titled "Zydus plans to launch innovative Semaglutide Injection in India on Day 1 of patent expiry, expanding patient access to GLP-1 therapy".</description>
</item>
<item>
<title>Press Release Feb 19 2026</title>
<link>https://6ix.com/company/zydus-lifesciences-limited/news/press-release-feb-19-2026-2</link>
<guid isPermaLink="true">https://6ix.com/company/zydus-lifesciences-limited/news/press-release-feb-19-2026-2</guid>
<pubDate>Fri, 20 Feb 2026 01:41:08 GMT</pubDate>
<description>Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 19, 2026, titled "Closure of USFDAinspection at Zydus Injectable plant at Ahmedabad".</description>
</item>
<item>
<title>Press Release Feb 18 2026</title>
<link>https://6ix.com/company/zydus-lifesciences-limited/news/press-release-feb-18-2026-3</link>
<guid isPermaLink="true">https://6ix.com/company/zydus-lifesciences-limited/news/press-release-feb-18-2026-3</guid>
<pubDate>Wed, 18 Feb 2026 23:07:52 GMT</pubDate>
<description>Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 18, 2026, titled "Zydus receives final approval from USFDA for Bosentan tablets for oral suspension, 32 mg".</description>
</item>
<item>
<title>Press Release Feb 17 2026</title>
<link>https://6ix.com/company/zydus-lifesciences-limited/news/press-release-feb-17-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/zydus-lifesciences-limited/news/press-release-feb-17-2026-1</guid>
<pubDate>Tue, 17 Feb 2026 15:18:13 GMT</pubDate>
<description>Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 17, 2026, titled "Zydus launches PEPAIR, a first in India, affordable, drug-free, handheld device for better respiratory health".</description>
</item>
<item>
<title>Press Release Feb 14 2026</title>
<link>https://6ix.com/company/zydus-lifesciences-limited/news/press-release-feb-14-2026</link>
<guid isPermaLink="true">https://6ix.com/company/zydus-lifesciences-limited/news/press-release-feb-14-2026</guid>
<pubDate>Sat, 14 Feb 2026 15:09:45 GMT</pubDate>
<description>Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 14, 2026, titled "Zydus receives final approval from USFDA for Ammonium Lactate Cream, 12%".</description>
</item>
</channel>
</rss>